<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effects of transforming growth factor-beta 1 (TGF-beta 1) on the growth of hematopoietic progenitors in <z:mpath ids='MPATH_458'>normal</z:mpath> donors and in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> now designed as clonal disorders of multipotential stem cells </plain></SENT>
<SENT sid="1" pm="."><plain>TGF-beta 1 at 80 pM exhibited differential effects on the <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoietic progenitors when cells were stimulated with different growth factors, such as G-CSF, GM-CSF, interleukin-3 (IL-3), or stem cell factor (SCF) </plain></SENT>
<SENT sid="2" pm="."><plain>The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, TGF-beta 1 suppression for growth with G-CSF was increased for <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) and <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera; <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase; <z:mp ids='MP_0005481'>CML</z:mp> in accelerated phase; <z:mp ids='MP_0005481'>CML</z:mp> in myeloid crisis; <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with an excess of blasts; and <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:mp ids='MP_0005481'>CML</z:mp>-myeloid crisis and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, TGF-beta 1 almost completely abolished the growth, with some patient-to-patient variation </plain></SENT>
<SENT sid="4" pm="."><plain>The mean ED50s for the growth of leukemic blast progenitors were 1.6, 1.2, 0.7, and 0.2 pM in the presence of G-CSF, GM-CSF, IL-3, and SCF, respectively, c-myc and c-myb antisense oligonucleotides significantly suppressed the growth of leukemic blast progenitors, but not that of clonogenic cells from <z:mpath ids='MPATH_458'>normal</z:mpath> donors and patients with ET </plain></SENT>
<SENT sid="5" pm="."><plain>We also demonstrated that TGF-beta 1 inhibits <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts for c-myc and/or c-myb </plain></SENT>
<SENT sid="6" pm="."><plain>When the data are taken together, growth suppression by TGF-beta 1 appears to increase with the progression of <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>